Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer.

Oncol Lett · 2018 · PMC6176362 · PMID 30344762

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

A retrospective comparative analysis in 550 patients (REGOTAS) ( 11 ) suggested that regorafenib should be given first in patients aged <65 years, but TAS-102 in patients aged ≥65 years, based on a favorable trend of OS.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.